ClinicalTrials.gg
CompletedNCT02878330MEDI8897 Ph2bUpdated Oct 14, 2019Results posted

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

A Phase 2 interventional study of MEDI8897 and Placebo in Respiratory Syncytial Virus Infections, sponsored by MedImmune LLC. Completed at 161 sites in 23 countries. Open to participants aged Up to 365 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-14.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,453
Allocation
Randomized
Ages
Up to 365 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
3rd of 12
1,453 · median 239
Started
2016
the only one that year
Phase 2
3 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 10th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: Up to 365 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.

Read the detailed description

This pivotal Phase 2b study will determine if MEDI8897 will be efficacious in reducing medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy preterm infants entering their first RSV season. The population to be enrolled is healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days GA who would not receive RSV prophylaxis. A total of 1500 infants will be randomized 2:1 to receive either MEDI8897 or placebo. Participants will be followed for 360 days after dosing. Enrollment is planned at approximately 197 sites across the USA, Canada, Europe, and the Southern Hemisphere.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus, RSV
  • Preterm Infants
  • Lower Respiratory Tract Infection
04

Who can participate

Ages eligible
Up to 365 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.
  2. Infants who are entering their first full RSV season at the time of screening.

Key Exclusion Criteria:

  1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.
  2. Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization.
  3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.
  4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.
  5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,453 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.

    Drug: Placebo

  • Experimental
    MEDI8897 50 mg

    Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.

    Drug: MEDI8897

Interventions

  • A single IM dose of 50 mg on Day 1 of the study.

  • DrugPlacebo

    A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)

    The determination of medically attended RSV LRTI is based on objective clinical LRTI criteria and RSV test results obtained from analyzing the respiratory secretions using a validated RSV real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of RSV A or RSV B subtypes. Criteria for LRTI included documented physical exam findings of rhonchi, rales, crackles, or wheeze and any of the following: increased respiratory rate at rest (for age less than (\<) 2 months: greater than or equal to (\>=) 60 breaths/min; 2-6 months: \>= 50 breaths/min; and for \> 6 months - 2 years, \>= 40 breaths/min), or hypoxemia (in room air - oxygen saturation \< 95% at altitudes less than or equal to (\<=) 1800 meters or \< 92% at altitudes \> 1800 meters), or clinical signs of severe respiratory disease or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid).

    Time frame: From Day 1 through Day 151

Secondary outcomes

  1. Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)

    A RSV hospitalization is defined as either 1) a respiratory hospitalization with a positive RSV test within 2 days of hospitalization (primary) or 2) new onset of respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial).

    Time frame: From Day 1 through Day 151

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: From Day 1 through Day 361

  3. Number of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs)

    An AESI was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor. An AESI may be serious or non-serious. A NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature. It is observed after receiving study drug and is assessed by investigator as medically significant.

    Time frame: From Day 1 through Day 361

  4. Serum Concentration of MEDI8897

    Time frame: Days 91, 151, and 361

  5. Elimination Half-life (t1/2) of MEDI8897

    Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Day 91 through Day 361

  6. Number of Participants With Positive Anti-drug Antibodies to MEDI8897

    The number of participants with positive serum antibodies to MEDI8897 are reported.

    Time frame: Days 91, 151, and 361

07

Results

Posted Oct 14, 2019

Participant flow

The study was conducted from 03-Nov-2016 to 06-Dec-2018.

Participant flow — Overall Study
MilestonePlaceboMEDI8897 50 mg
Started484969
Completed455913
Not completed2956
Withdrew: Death32
Withdrew: Lost to follow-up1126
Withdrew: Withdrawal by subject1121
Withdrew: Other47

Outcome measures

PrimaryNumber of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)

The determination of medically attended RSV LRTI is based on objective clinical LRTI criteria and RSV test results obtained from analyzing the respiratory secretions using a validated RSV real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of RSV A or RSV B subtypes. Criteria for LRTI included documented physical exam findings of rhonchi, rales, crackles, or wheeze and any of the following: increased respiratory rate at rest (for age less than (\<) 2 months: greater than or equal to (\>=) 60 breaths/min; 2-6 months: \>= 50 breaths/min; and for \> 6 months - 2 years, \>= 40 breaths/min), or hypoxemia (in room air - oxygen saturation \< 95% at altitudes less than or equal to (\<=) 1800 meters or \< 92% at altitudes \> 1800 meters), or clinical signs of severe respiratory disease or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid).

Time frame:
From Day 1 through Day 151
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)
ParticipantsPlaceboMEDI8897 50 mg
Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)4625
Statistical analysis
  • Placebo vs MEDI8897 50 mg · Poisson regression · p = <0.0001 · Relative risk reduction: 70.1 · 95% CI 52.3 to 81.2
SecondaryNumber of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)

A RSV hospitalization is defined as either 1) a respiratory hospitalization with a positive RSV test within 2 days of hospitalization (primary) or 2) new onset of respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial).

Time frame:
From Day 1 through Day 151
Reported as:
Count of participants · Participants
Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)
ParticipantsPlaceboMEDI8897 50 mg
Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)208
Statistical analysis
  • Placebo vs MEDI8897 50 mg · Poisson regression · p = 0.0002 · Relative risk reduction: 78.4 · 95% CI 51.9 to 90.3
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
From Day 1 through Day 361
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI8897 50 mg
TEAEs416834
TESAEs81108
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs)

An AESI was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor. An AESI may be serious or non-serious. A NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature. It is observed after receiving study drug and is assessed by investigator as medically significant.

Time frame:
From Day 1 through Day 361
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs)
ParticipantsPlaceboMEDI8897 50 mg
AESIs35
NOCDs44
SecondarySerum Concentration of MEDI8897
Time frame:
Days 91, 151, and 361
Reported as:
Mean · mcg/mL
Serum Concentration of MEDI8897
mcg/mLMEDI8897 50 mg
Day 9135.9 ± 10.9
Day 15118.9 ± 7.4
Day 3612.1 ± 1.1
SecondaryElimination Half-life (t1/2) of MEDI8897

Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the serum.

Time frame:
Day 91 through Day 361
Reported as:
Mean · Days
Elimination Half-life (t1/2) of MEDI8897
DaysMEDI8897 50 mg
Elimination Half-life (t1/2) of MEDI889759.3 ± 9.6
SecondaryNumber of Participants With Positive Anti-drug Antibodies to MEDI8897

The number of participants with positive serum antibodies to MEDI8897 are reported.

Time frame:
Days 91, 151, and 361
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies to MEDI8897
ParticipantsPlaceboMEDI8897 50 mg
Day 91411
Day 151617
Day 361830

Adverse events

Collected over From Day 1 through Day 361. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo3/479 (0.6%)81/479 (16.9%)402/479 (83.9%)
MEDI8897 50 mg2/968 (0.2%)108/968 (11.2%)804/968 (83.1%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventPlaceboMEDI8897 50 mg
BronchiolitisInfections and infestations21/47920/968
Lower respiratory tract infectionInfections and infestations13/47914/968
BronchitisInfections and infestations11/47914/968
PneumoniaInfections and infestations10/47913/968
Inguinal herniaGastrointestinal disorders6/4791/968
GastroenteritisInfections and infestations4/4799/968
Urinary tract infectionInfections and infestations4/4790/968
Pneumonia viralInfections and infestations2/4797/968
Lower respiratory tract infection viralInfections and infestations3/4795/968
Upper respiratory tract infectionInfections and infestations3/4793/968
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPlaceboMEDI8897 50 mg
Upper respiratory tract infectionInfections and infestations169/479392/968
NasopharyngitisInfections and infestations94/479164/968
PyrexiaGeneral disorders63/479109/968
GastroenteritisInfections and infestations44/479115/968
RhinitisInfections and infestations50/479111/968
DiarrhoeaGastrointestinal disorders49/47998/968
BronchitisInfections and infestations49/47991/968
Lower respiratory tract infectionInfections and infestations46/47975/968
ConjunctivitisInfections and infestations39/47986/968
BronchiolitisInfections and infestations42/47983/968

Baseline characteristics

The intent-to-treat (ITT) population included all participants who were randomized in the study and analyzed according to their randomized treatment group.

Age, Continuous
Age, Continuous(Months)PlaceboMEDI8897 50 mgTotal
Mean3.28 ± 2.313.29 ± 2.223.29 ± 2.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI8897 50 mgTotal
Female224468692
Male260501761
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMEDI8897 50 mgTotal
Hispanic or Latino91225316
Not Hispanic or Latino3937431136
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMEDI8897 50 mgTotal
American Indian or Alaska Native101
Asian10515
Native Hawaiian or Other Pacific Islander3811
Black or African American67189256
White3556931048
More than one race51217
Unknown or Not Reported4362105
08

Study locations

161 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Anaheim, California 92804, United States
  • Research Site
    Anaheim, California 92805, United States
  • Research Site
    Downey, California 90241, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Paramount, California 90723, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    West Covina, California 91790, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Colorado Springs, Colorado 80922, United States
  • Research Site
    Hartford, Connecticut 06106, United States
  • Research Site
    Gainesville, Florida 32607, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    South Miami, Florida 33143, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Oak Lawn, Illinois 60068, United States
  • Research Site
    Park Ridge, Illinois 60068, United States
  • Research Site
    South Bend, Indiana 46601, United States
  • Research Site
    Woburn, Massachusetts 01801, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Jackson, Mississippi 39216, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    Lincoln, Nebraska 68504, United States
  • Research Site
    Omaha, Nebraska 68124, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New Hyde Park, New York 11040, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Syracuse, New York 13210-2306, United States
  • Research Site
    Boone, North Carolina 28607, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Cleveland, Ohio 44109, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Columbus, Ohio 43231, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Gresham, Oregon 97030, United States
  • Research Site
    Erie, Pennsylvania 16506, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Sioux Falls, South Dakota 57104, United States
  • Research Site
    Memphis, Tennessee 38103, United States
  • Research Site
    Edinburg, Texas 78539, United States
  • Research Site
    Fort Worth, Texas 76107, United States
  • Research Site
    Galveston, Texas 77555, United States
  • Research Site
    Longview, Texas 75605, United States
  • Research Site
    San Antonio, Texas 78249, United States
  • Research Site
    Layton, Utah 84041, United States
  • Research Site
    Orem, Utah 84057, United States
  • Research Site
    Syracuse, Utah 84075, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Huntington, West Virginia 25701, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Bahía Blanca, B8001HXM, Argentina
  • Research Site
    Guaymallen Mendoza, 5519, Argentina
  • Research Site
    Parkville, 3052, Australia
  • Research Site
    Subiaco, 6008, Australia
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Mons, 7000, Belgium
  • Research Site
    Botucatu, 18618-970, Brazil
  • Research Site
    Campinas, 13084-791, Brazil
  • Research Site
    Canoas, 92425-900, Brazil
  • Research Site
    Curitiba, 80250-060, Brazil
  • Research Site
    Juiz de Fora, 36025-330, Brazil
  • Research Site
    Passo Fundo, 99010-080, Brazil
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Maipu, 9250000, Chile
  • Research Site
    Santiago, 8053095, Chile
  • Research Site
    Santiago, 8380453, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Santiago, 8880465, Chile
  • Research Site
    Valdivia, 5090000, Chile
  • Research Site
    Viña del Mar, 2520594, Chile
  • Research Site
    Havlickuv Brod, 580 22, Czechia
  • Research Site
    Praha 4, 14059, Czechia
  • Research Site
    Praha 4, 14710, Czechia
  • Research Site
    Tallinn, 13419, Estonia
  • Research Site
    Tartu, 50406, Estonia
  • Research Site
    Tampere, 33100, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Bron, 69677, France
  • Research Site
    Caen Cedex, 14033, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Tours CEDEX 9, 37044, France
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Budapest, 1094, Hungary

Showing the first 100 of 161 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simoes EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. Erratum In: N Engl J Med. 2020 Aug 13;383(7):698. doi: 10.1056/NEJMx200019. PubMed 32726528 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Oct 2019, 1 year 2 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 20 months is above that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2016
First posted
Aug 25, 2016
StartActual
Nov 3, 2016
Primary completionActual
Jul 17, 2018
CompletionActual
Dec 6, 2018
Results first posted
Oct 14, 2019
Last update
Oct 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02878330
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Nov 3, 2016
Primary completion
Jul 17, 2018
Completion
Dec 6, 2018
Results posted
Oct 14, 2019
Last update
Oct 14, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion